Megace Es
Endometrial Neoplasms, Endometrial Neoplasms, Acquired Immunodeficiency Syndrome + 7 more
Treatment
7 Active Studies for Megace Es
Treatment for
Endometrial Neoplasms
What is Megace Es
Megestrol acetate
The Generic name of this drug
Treatment Summary
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione is a hormone used to treat various conditions. It is usually prescribed in the form of an acetate ester and is more powerful than progesterone. It is used to suppress ovulation and as a way to manage certain types of breast cancer.
Megestrol Acetate
is the brand name
Megace Es Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Megestrol Acetate
Megestrol acetate
1988
76
Effectiveness
How Megace Es Affects Patients
Megestrol is a synthetic form of the hormone progesterone, which affects the endometrium, body temperature, and pituitary gland. It also has a small effect on glucocorticoid and mineralocorticoid hormones. This drug does not have any estrogenic, androgenic, or anabolic effects. The exact way it works to reduce appetite and cachexia (wasting) is unknown. It was originally developed as a contraceptive, but was later found to be useful in treating breast cancer.
How Megace Es works in the body
We don't know exactly how megestrol acetate works, but it likely has something to do with suppressing hormones that control appetite. It also seems to change how the body breaks down food, which may help explain why it causes weight gain. Megestrol may also interfere with hormones that prevent fat from being stored in the body.
When to interrupt dosage
The endorsed dosage of Megace Es relies upon the determined condition, including Recurrent Endometrial Carcinoma, Breast and Endometrial Carcinoma. The quantity of dosage fluctuates as per the method of delivery (e.g. Oral or Suspension - Oral) noted in the table beneath.
Condition
Dosage
Administration
Endometrial Neoplasms
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Endometrial Neoplasms
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Acquired Immunodeficiency Syndrome
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Palliative Treatment
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Anorexia
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Breast
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Endometrial Carcinoma
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Weight decreased
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Breast
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Breast
, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL
Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral
Warnings
Megace Es Contraindications
Condition
Risk Level
Notes
suspected pregnancy
Do Not Combine
There are 20 known major drug interactions with Megace Es.
Common Megace Es Drug Interactions
Drug Name
Risk Level
Description
Dofetilide
Major
Megestrol acetate may decrease the excretion rate of Dofetilide which could result in a higher serum level.
Tranexamic acid
Major
Megestrol acetate may increase the thrombogenic activities of Tranexamic acid.
Abacavir
Minor
Megestrol acetate may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetohexamide
Minor
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Megestrol acetate.
Aclidinium
Minor
Megestrol acetate may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Megace Es Toxicity & Overdose Risk
Studies have not reported any serious side effects from taking megestrol acetate oral suspension in doses up to 1200 mg/day. Taking megestrol acetate, a drug that increases the appetite, can lead to suppression of the adrenal glands. This is thought to be due to the drug's effects on the body's cortisol production.
Megace Es Novel Uses: Which Conditions Have a Clinical Trial Featuring Megace Es?
315 active clinical trials are currently being conducted to assess the potential of Megace Es to reduce metastatic Endometrial Carcinoma, Cachexia and Breast Disease.
Condition
Clinical Trials
Trial Phases
Endometrial Neoplasms
0 Actively Recruiting
Endometrial Carcinoma
0 Actively Recruiting
Palliative Treatment
1 Actively Recruiting
Phase 3
Anorexia
1 Actively Recruiting
Phase 1
Breast
0 Actively Recruiting
Breast
0 Actively Recruiting
Breast
0 Actively Recruiting
Weight decreased
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
4 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Endometrial Neoplasms
0 Actively Recruiting
Megace Es Reviews: What are patients saying about Megace Es?
5
Patient Review
2/15/2008
Megace Es for Loss of Appetite with HIV
4.3
Patient Review
9/16/2008
Megace Es for Decrease in Weight due to HIV Infection
4.3
Patient Review
12/8/2008
Megace Es for Metastatic Endometrial Carcinoma
1
Patient Review
4/18/2012
Megace Es for Cancer in the Lining of the Uterus
Patient Q&A Section about megace es
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.